Sign In
Buy CVAC
$4.66
+0 (+0%)
At Close: Apr 02, 2026
CureVac Announces Financial Results for the Second Quarter and First Half of 2024 and Provides Business Update
07:30am, Thursday, 15'th Aug 2024
Closed new licensing agreement with GSK worth up to €1.45 billion, including €400 million upfront; provides strong validation of CureVac's mRNA platform Initiated strategic workforce reduction of
CureVac Advances Cancer Vaccine Candidate CVGBM to Part B of Phase 1 Study in Patients with Resected Glioblastoma
07:20am, Thursday, 15'th Aug 2024
First patient administered in dose-confirmation Part B of Phase 1 study with mRNA-based, multiepitope cancer vaccine candidate CVGBM Part B expected to include up to 20 patients to generate extended d
CureVac Names Oncologist and Drug Development Expert Dr. Mehdi Shahidi to Supervisory Board
07:15am, Thursday, 15'th Aug 2024
TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / August 15, 2024 / CureVac N.V. (Nasdaq:CVAC) ("CureVac"), a global biopharmaceutical company developing a new class of transformative medicines based o
CureVac N.V. (CVAC) Expected to Beat Earnings Estimates: Should You Buy?
11:00am, Thursday, 08'th Aug 2024
CureVac (CVAC) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
CureVac (CVAC) Upgraded to Buy: What Does It Mean for the Stock?
01:01pm, Monday, 15'th Jul 2024
CureVac (CVAC) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
CureVac Provides Update on Trial Dates for Patent Litigation Across Multiple Geographies Against Pfizer/BioNTech
07:15am, Thursday, 11'th Jul 2024
New trial date for U.S. patent litigation set for March 3, 2025, following settlement with Acuitas Therapeutics First instance decision on validity of EP 3 708 668 B1 (split poly-A tail technology) sc
Agomab Bolsters Executive Team with Appointment of Pierre Kemula as Chief Financial Officer
07:00am, Thursday, 11'th Jul 2024
ANTWERP, Belgium--(BUSINESS WIRE)--Agomab Therapeutics NV (‘Agomab') today announced that Pierre Kemula will join the company as Chief Financial Officer (CFO) effective November 1, 2024, bringing mo
CureVac Layoffs 2024: What to Know About the Latest CVAC Job Cuts
11:49am, Wednesday, 03'rd Jul 2024
CureVac (NASDAQ: CVAC ) layoffs are coming for the vaccine maker's employees as it prepares to undergo a restructuring to streamline its business. CureVac has announced that its layoffs will affect 30
GSK Will Pay Up to $1.5 Billion for CureVac's mRNA Vaccines
10:18am, Wednesday, 03'rd Jul 2024
The deal represents a vote of confidence in the future of the mRNA-based vaccine market.
CVAC Stock Alert: CureVac Pops on Licensing Deal With GSK
10:09am, Wednesday, 03'rd Jul 2024
CureVac (NASDAQ: CVAC ) stock is on the rise Wednesday after the company announced a restructured licensing agreement with GSK (NYSE: GSK ). This new agreement has GSK taking over the development and
CureVac's stock soars on GSK's $1.56 billion deal for its COVID-19 and flu vaccines
07:53am, Wednesday, 03'rd Jul 2024
U.S.-listed shares of CureVac NV surged on Wednesday after GSK PLC announced an offer worth up to $1.56 billion (€1.44 billion) for the rights to the German biopharmaceutical's COVID-19 and flu vacc
CureVac Initiates Strategic Restructuring to Align Resources with Focus on High-Value mRNA Pipeline Opportunities
02:40am, Wednesday, 03'rd Jul 2024
Strategic restructuring includes a workforce reduction of approximately 30%, re-focusing on research, development, and innovation to create leaner and more agile organization Prioritization of high-va
GSK and CureVac to Restructure Collaboration into New Licensing Agreement
02:40am, Wednesday, 03'rd Jul 2024
GSK acquires full rights to develop, manufacture and commercialize globally mRNA candidate vaccines for influenza and COVID-19, including combinations CureVac receives €400 million upfront and up to
GSK buys full rights to make COVID, influenza vaccines from CureVac
02:26am, Wednesday, 03'rd Jul 2024
GSK has bought from CureVac 5CV.DE, CVAC.O the full rights to develop and manufacture vaccine candidates for influenza and COVID-19 that use messenger RNA (mRNA) technology for up to 1.05 billion euro
CureVac Announces Voting Results of General Meeting
04:20pm, Monday, 24'th Jun 2024
TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / June 24, 2024 / CureVac N.V. (NASDAQ:CVAC), a global clinical-stage biopharmaceutical company developing a new class of transformative medicines based
